EUCTR2021-002482-17-PL进行中（未招募）1 期
A Phase 3, Prospective, Open-Label, Multisite, Extension of Phase 3 Studies To Assess the Long-Term Safety and Tolerability of Soticlestat as Adjunctive Therapy in Subjects With Dravet Syndrome or Lennox-Gastaut Syndrome (ENDYMION 2).
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 400
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •Been previously enrolled in a phase 3 soticlestat clinical study.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 282
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 118
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Unstable, clinically significant neurologic (other than the disease being studied), psychiatric, cardiovascular, ophthalmologic, pulmonary, hepatic, renal, metabolic, gastrointestinal, urologic, immunologic, hematopoietic, endocrine disease, malignancy including progressive tumors, or other abnormality that may impact the ability to participate in the study or that may potentially confound the study results. It is the responsibility of the investigator to assess the clinical significance; however, consultation with the medical monitor may be warranted.
- •2. Abnormal and clinically significant ECG abnormality at Visit 1 including QT interval with Fridericia correction method (QTcF) >450 ms confirmed with a repeat ECG using manual measurement of QTcF.
- •3. Participant is considered by the investigator to be at imminent risk of suicide or injury to self, others, or property. Participants who have positive answers on item numbers 4 or 5 on the CSSRS before dosing are excluded. This scale will only be administered to subjects aged =6 years.
研究者
相似试验
进行中（未招募）
1 期
Open-Label Extension Study of Soticlestat in Dravet and Lennox-Gastaut SyndromesEUCTR2021-002482-17-BETakeda Development Center Americas, Inc400
进行中（未招募）
1 期
Open-Label Extension Study of Soticlestat in Dravet and Lennox-Gastaut SyndromesDravet Syndrome (DS)Lennox-Gastaut Syndrome (LGS)MedDRA version: 20.0Level: LLTClassification code 10073682Term: Dravet syndromeSystem Organ Class: 100000004850MedDRA version: 20.1Level: PTClassification code 10048816Term: Lennox-Gastaut syndromeSystem Organ Class: 10029205 - Nervous system disordersEUCTR2021-002482-17-NLTakeda Development Center Americas, Inc400
进行中（未招募）
1 期
Open-Label Extension Study of Soticlestat in Dravet and Lennox-Gastaut SyndromesDravet Syndrome (DS)Lennox-Gastaut Syndrome (LGS)MedDRA version: 20.0Level: LLTClassification code 10073682Term: Dravet syndromeSystem Organ Class: 100000004850MedDRA version: 20.1Level: PTClassification code 10048816Term: Lennox-Gastaut syndromeSystem Organ Class: 10029205 - Nervous system disordersEUCTR2021-002482-17-HUTakeda Development Center Americas, Inc376
招募中
3 期
A Phase 3, Prospective, Open-Label, Multisite, Extension of Phase 3 Studies to Assess the Long-Term Safety and Tolerability of Soticlestat as Adjunctive Therapy in Subjects With Dravet Syndrome or Lennox-Gastaut Syndrome (ENDYMION 2)NL-OMON53987Takeda21
进行中（未招募）
1 期
Open-Label Extension Study of Soticlestat in Dravet and Lennox-Gastaut SyndromesEUCTR2021-002482-17-LVTakeda Development Center Americas, Inc376